Similar immune activation trends were reported in a phase I clinical trial using inhaled recombinant human IL-15 in dogs with metastatic melanoma or osteosarcoma, where cytokine induction and increased PBMC cytotoxicity correlated with clinical benefit. This evidence concerns the gene IL15 and metastatic melanoma.